Eine vielfältige klinische und zellbiologisch-experimentelle Forschungslandschaft trägt dazu bei, dass gerade beim metastasierten Mammakarzinom die zunehmenden therapeutischen Alternativen einer medikamentösen Behandlung nicht nur einem steten Wandel unterworfen sind, sondern glücklicherweise auch zu einer schrittweisen Verbesserung der Langzeitergebnisse führen [1]. Wie bei der einzelnen Patientin zu verfahren ist, wird durch die onkologischen Therapeuten oft recht unterschiedlich beurteilt. Auch aus Sicht der Autoren sind bei den zahlreichen unterschiedlichen Situationen eines Langzeitverlaufs die Behandlungsmöglichkeiten heterogen. Diese können durch die gegenwärtige Studienmedizin nur teilweise abgebildet werden [2]. Deshalb sind Vorgaben durch vereinfachende Leitlinien von Fachgesellschaften auch nicht immer befriedigend.
Literatur
Giordano SH, Budzar AU, Smith TL et al. (2004) Is breast cancer survival improving? Cancer 100: 44–52
Seeber S, Braun AH (2005) Phase III trials in oncology: setting standards of care? Nat Clin Pract Oncol 2: 426–427
Miller K, Wang M, Gralow J et al. (2007) Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med 357: 2666–2676
Fisher B, Brown A, Mamounas E et al. (1997) Effect of preoperative chemotherapy on local-regional disease in women with operable breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-18. J Clin Oncol 15: 2483–2493
O'Shaughnessy J, Miles D, Vukelja S et al. (2002) Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer. J Clin Oncol 20: 2812–2823
Feher O, Vodvarka P, Jassem J et al. (2005) First-line gemcitabine versus epirubicin in postmenopausal women aged 60 or older with metastatic breast cancer: a multicenter, randomized, phase III study. Ann Oncol 16: 899–908
Sledge GW, Neuberg D, Bernardo P et al. (2003) Phase III trial of doxorubicin, paclitaxel, and the combination of doxorubicin and paclitaxel as front-line chemotherapy for metastatic breast cancer: an intergroup trial (E1193). J Clin Oncol 21: 588–592
Welt A, Minckwitz G v, Oberhoff C et al. (2005) Phase I/II study of capecitabine and vinorelbine in pretreated patients with metastatic breast cancer. Ann Oncol 16: 64–69
Bojko P, Welt A, Schleucher R et al. (2004) High-dose chemotherapy with autologous stem cell transplantation in patients with oligometastatic breast cancer. Bone Marrow Transplant 34: 637–643
Hortobagyi GN (2002) Can we cure limited metastatic breast cancer? J Clin Oncol 20: 620–623
Goncalves A, Deblock M, Esterni B et al. (2007) Serum proteomic prediction of progression-free survival in HER2-negative metastatic breast cancer patients receiving docetaxel as first-line treatment. J Clin Oncol (ASCO Meeting Abstract) 25: 1010
Kaufman PA, Broadwater G, Lezon-Geyda K et al. (2007) CALGB 150002: Correlation of HER2 and chromosome 17 (ch17) copy number with trastuzumab (T) efficacy in CALGB 9840, paclitaxel (P) with or without T in HER2+ and HER2− metastatic breast cancer (MBC). J Clin Oncol (ASCO Meeting Abstract) 25: 1009
Lin NU, Dieras V, Paul D et al. (2007) EGF105084, a phase II study of lapatinib for brain metastases in patients (pts) with HER2+ breast cancer following trastuzumab (H) based systemic therapy and cranial radiotherapy (RT). J Clin Oncol (ASCO Meeting Abstract) 25: 1012
Seidman A (2005) „Will weekly work“? Seems to be so… . J Clin Oncol 23: 5873–5874
Verrill MW, Lee J, Cameron A et al. (2007) Anglo-Celtic IV: First results of a UK National Cancer Research Network randomised phase 3 pharmacogenetic trial of weekly versus 3 weekly Paclitaxel in patients with locally advanced or metastatic breast cancer. J Clin Oncol (ASCO Meeting Abstract) 25: 1005
Alba E, Ruiz-Borrego M, Martín M et al. (2007) Prolongation of TTP by maintenance therapy with PLD in a multicenter phase III randomited trial following standard chemotherapy for MBC: GEICAM 2001–01 study. J Clin Oncol (ASCO Meeting Abstract) 25: 1007
Slamon DJ, Mackey J, Robert N et al. (2007) Role of anthracycline- based therapy in the adjuvant treatment of breast cancer: Efficacy analyses determined by molecular subtypes of the disease. 30th Annual San Antonio Breast Cancer Symposium: Abstr. 13
Rakha EA, El-Sayed ME, Reis-Filho J, Ellis IO (2008) Patho-biological aspects of basal-like breast cancer. Breast Cancer Res Treat. 2008 Mar 9 [Epub ahead of print]
Rugo HS, Thomas ES, Lee RK et al. (2007) Combination therapy with the novel epothilone B analog, ixabepilone, plus capecitabine has efficacy in ER/PR/HER2-negative breast cancer resistant to anthracyclines and taxanes. 30th Annual San Antonio Breast Cancer Symposium: Abstr. 6069
Welt A, Schütte J, Seeber S (2007) Mammakarzinom. In: Seeber S, Schütte J (Hrsg) Therapiekonzepte Onkologie. 5. Aufl., Springer, Berlin, S 1119–1183
Walter C (2008) Nichtpublizierte Fallsammlung von Patientinnen mit Langzeitüberleben bei metastasiertem Mammakarzinom der Inneren Klinik (Tumorforschung) des Universitätsklinikums Essen
Author information
Authors and Affiliations
Corresponding authors
Rights and permissions
About this article
Cite this article
Seeber, S., Welt, A. Das metastasierte Mammakarzinom. best practice onkologie 3, 4–16 (2008). https://doi.org/10.1007/s11654-008-0047-6
Issue Date:
DOI: https://doi.org/10.1007/s11654-008-0047-6